[ET Net News Agency, 16 November 2021] Luye Pharma Group Ltd. (02186) said the group
has submitted the investigational new drug application for its new central nervous system
(CNS) drug LY03009 to the Food and Drug Administration of the United States of America.
LY03009 is indicated for the treatment of Parkinson's disease and restless legs
syndrome. It is developed on the group's long-acting and extended release technology
platform. (RC)